Skip to main content

Advertisement

SpringerLink
Log in

Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the united states?

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

In the quest for “evidence-based” medicine, an accepted hierarchy of evidence has been proposed. This hierarchy places in vitro studies and animal data at the base, and puts systematic reviews, meta-analyses, and randomized controlled trials at the pinnacle. However, when clinical medicine faces questions that have not yet been studied by the “gold standard” methods, how is one to proceed? Often, the best evidence at hand falls short of randomized controlled trials and meta-analyses. Using this framework, a review of the evidence supporting the hypothesis that population-wide diuretic use is directly associated with end-stage renal disease in the United States is presented. Publications pertaining to diuretic use in recent clinical trials are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Goldman L, Cook EF: The decline in ischemic heart disease mortality rates. An analysis of the comparative effects of medical interventions and changes in lifestyle. Ann Intern Med 1984, 101:825–836.

    PubMed  CAS  Google Scholar 

  2. Gallup G Jr, Cotugno HE: Preferences and practices of Americans and their physicians in antihypertensive therapy. Am J Med 1986, 81:20–24.

    Article  PubMed  Google Scholar 

  3. Hawkins RG, Houston MC: Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis. Am J Hypertens 2005, 18:744–749. This article presents the origins of the hypothesis that diuretic-based therapies may not be ideally renoprotective.

    Article  PubMed  Google Scholar 

  4. Russell A, Remington P, D’Alessio D, Brazy P: Increasing incidence of end-stage renal disease in Wisconsin: An unintended consequence of increased survival? WMJ 2001, 100:35–38.

    PubMed  CAS  Google Scholar 

  5. Brenner BM: Brenner and Rector’s The Kidney, edn 6. Philadelphia: WB Saunders; 2000:135.

    Google Scholar 

  6. Komatsu K, Numabe A, Ono Y, Frohlich ED: Hydrochlorothiazide increases efferent glomerular arteriolar resistance in spontaneously hypertensive rats. J Cardiovasc Pharm Ther 1996, 1:57–64.

    CAS  Google Scholar 

  7. Westphal S, Rading A, Luley C, Dierkes J: Antihypertensive treatment and homocysteine concentrations. Metabolism 2003, 52:261–263.

    Article  PubMed  CAS  Google Scholar 

  8. Lottermoser K, Hertfelder HJ, Vetter H, Dusing R: Fibrinolytic function in diuretic-induced volume depletion. Am J Hypertens 2000, 13:359–363.

    Article  PubMed  CAS  Google Scholar 

  9. Mikhail N, Fukuda N, Tremblay J, Hamet P: Platelets, growth factors, and vascular smooth-muscle cells in hypertension and diabetes. J Cardiovasc Pharmacol 1993, 22(Suppl 6):S64-S74.

    PubMed  CAS  Google Scholar 

  10. Kasiske BL, Ma JZ, Kalil RSN, Louis TA: Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995, 122:133–141.

    PubMed  CAS  Google Scholar 

  11. Ohman KP, Karlberg BE, Nilsson OR, Wettre S: Captopril, aldosterone and urinary kallikrein in primary hypertension. Clin Exp Hypertens A 1983, 5:523–529.

    Article  PubMed  CAS  Google Scholar 

  12. Benigni A, Zoja C, Noris M, et al.: Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. Am J Kidney Dis 1999, 33:746–753.

    PubMed  CAS  Google Scholar 

  13. Roman MJ, Alderman MH, Pickering TG, et al.: Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy. Am J Hypertens 1998, 11:387–396.

    Article  PubMed  CAS  Google Scholar 

  14. Klahr S, Morrissey J: Progression of chronic renal disease. Am J Kidney Dis 2003, 41:S3-S7.

    PubMed  CAS  Google Scholar 

  15. Mann B, Hartner A, Jensen BL, et al.: Furosemide stimulates macula densa cyclooxygenase-2 expression in rats. Kidney Int 2001, 59:62–68.

    Article  PubMed  CAS  Google Scholar 

  16. Wang JL, Cheng HF, Shappell S, Harris RC: A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progression of renal injury in rats. Kidney Int 2000, 57:2334–2342.

    Article  PubMed  CAS  Google Scholar 

  17. Ono Y, Ono H, Frohlich ED: Hydrochlorothiazide exacerbates nitric oxide-blockade nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats. J Hypertens 1996, 14:823–828.

    Article  PubMed  CAS  Google Scholar 

  18. Francischetti A, Ono H, Frohlich ED: Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME. Hypertension 1998, 31:795–801.

    PubMed  CAS  Google Scholar 

  19. Nakamura Y, Ono H, Zhou X, Frohlich ED: Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in N(omega)-nitro-L-arginine methyl ester/ spontaneously hypertensive rats. Hypertension 2001, 37:1262–1267.

    PubMed  CAS  Google Scholar 

  20. Madkour H, Gadallah M, Riveline B, et al.: Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension. Am J Nephrol 1995, 15:251–255.

    PubMed  CAS  Google Scholar 

  21. Rajapakse JC, DeCarli C, McLaughlin A, et al.: Cerebral magnetic resonance image segmentation using data fusion. Neuroradiology 1996, 20:206–218.

    CAS  Google Scholar 

  22. Mitiche A, Aggarwal JK: Multiple sensor integration/ fusion through image processing: a review. Opt Eng 1986, 25:380–386.

    Google Scholar 

  23. Luo RC, Kay MG: Multisensor integration and fusion in intelligent systems. IEEE Trans Systems Man Cybernet 1989, 19:909–931.

    Article  Google Scholar 

  24. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157:2413–2446.

  25. Psaty BM, Lumley T, Furberg CD, et al.: Health outcomes associated with various antihypertensive therapies used as first-line agents. JAMA 2003, 289:2534–2544.

    Article  PubMed  CAS  Google Scholar 

  26. Medical Research Council Working Party: MRC trial of treatment of mild hypertension: principal results. Br Med J (Clin Res Ed) 1985, 291:97–104.

    Google Scholar 

  27. Fletcher A, Amery A, Birkenhager W, et al.: Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. J Hypertens 1991, 9:225–230.

    Article  PubMed  CAS  Google Scholar 

  28. Coope J, Warrender TS: Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986, 293:1145–1151.

    PubMed  CAS  Google Scholar 

  29. Ekbom T, Dahlof B, Hansson L, et al.: Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOPHypertension study. J Hypertens 1992, 10:1525–1530.

    Article  PubMed  CAS  Google Scholar 

  30. Coresh J, Wei G L, McQuillan G, et al.: Prevalence of high blood pressure and elevated serum creatinine level in the United States. Arch Intern Med 2001, 161:1207–1216.

    Article  PubMed  CAS  Google Scholar 

  31. Voyaki SM, Staessen JA, Thijs L, et al.: Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J Hypertens 2001, 19:511–519.

    Article  PubMed  CAS  Google Scholar 

  32. Savage PJ, Pressel SL, Curb JD, et al.: Influence of longterm low-dose diuretic-based antihypertensive therapy on glucose, lipid, uric acid and potassium levels in older men and women with isolated systolic hypertension. The Systolic Hypertension in the Elderly Program. Arch Intern Med 1999, 158:741–751.

    Article  Google Scholar 

  33. Brown MJ, Palmer CR, Castaigne A, et al.: Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000, 356:366–372.

    Article  PubMed  CAS  Google Scholar 

  34. The ALLHAT Study Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs. diuretic. JAMA 2002, 288:2981–2997.

    Article  Google Scholar 

  35. Dahlof B, Sever PS, Poulter NR, et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentered randomised controlled trial. For the ASCOT Investigators. Lancet 2005, 366:907–913. This study is a landmark comparison of traditional versus contemporary treatment regimens. It is a “must read” paper for anyone who treats primary hypertension.

    Article  PubMed  CAS  Google Scholar 

  36. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group Preserving Renal Function in Adults with Hypertension and Diabetes: A Consensus Approach. Am J Kidney Dis 2000, 36:646–661.

    Google Scholar 

  37. Rahman M, Pressel S, Davis B, et al.: Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic. For the ALLHAT Collaborative Research Group. Arch Intern Med 2005, 165:936–946. This study represents the largest single trial examining renal outcomes with antihypertensive therapies. It should be read to evaluate the claims of the ALLHAT research group of treatment equivalence, which is not evident in the data.

    Article  PubMed  CAS  Google Scholar 

  38. Psaty BM, Lumley T, Furberg CD: Research Letter. Metaanalysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. JAMA 2004, 292:43–44.

    Article  PubMed  CAS  Google Scholar 

  39. Casas JP, Chua W, Loukogeorgakis S, et al.: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005, 10:2026–2026. An interesting study with inconclusive results. It represents the best published effort to date to meta-analyze the data on renal protection according to medication categories. The data are heavily influenced by the huge ALLHAT trial population.

    Article  CAS  Google Scholar 

  40. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. For the Collaborative Study Group. N Engl J Med 2001, 345:851–860.

    Article  PubMed  CAS  Google Scholar 

  41. Medscape article accessed on Jan 8, 2005 at: http://www. medscape.com/viewarticle/456055

  42. Moser M, MacAulay AI: Chlorothiazide as an adjunct in the treatment of essential hypertension. Am J Cardiol 1959, 2:214–219.

    Article  Google Scholar 

  43. Basile J: Analysis of recent papers in hypertension. Does diuretic use lead to an increased risk of subsequent endstage renal disease? J Clin Hypertens 2005, 7:491–492.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hypertension and Nephrology, Manitoba Clinic, 790 Sherbrook Street, Winnipeg, Manitoba, Canada R3A 1M3

    Ralph G. Hawkins MD, LLM, FRCPC

Authors
  1. Ralph G. Hawkins MD, LLM, FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ralph G. Hawkins MD, LLM, FRCPC.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hawkins, R.G. Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the united states?. Current Science Inc 8, 219–225 (2006). https://doi.org/10.1007/s11906-006-0054-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-006-0054-3

Keywords

Search

Navigation